Findings lay groundwork for human clinical trial planned for August 2016
A new scientific study has identified why colorectal cancer cells depend on a specific nutrient, and a way to starve them of it. Over one million men and women are living with colorectal cancer in the United States. The National Cancer Institute estimates 4.5% of all men and women will be diagnosed with the cancer during their lifetime, making it the third most common non-skin cancer.
In the study published online in Nature Communications, researchers showed how certain colorectal cancer cells reprogram their metabolism using glutamine, a non-essential amino acid. Many cancer cells rely on glutamine to survive. How they become so dependent on the molecule is hotly debated in the field.
Researchers studied a subset of colorectal cancer cells containing a genetic mutation called PIK3CA. This mutation is located in a gene critical for cell division and movement, and is found in approximately one third of all colorectal cancers. The mutation is also the most commonly identified genetic mutation across all cancers, making the results of the study universally appealing.
Researchers were interested in determining whether or not the common PIK3CA mutation contributes to changes in cancer cell metabolism, such as how nutrients like glutamine are processed. Normally, glutamine is broken down by cancer cells into several other molecules with the help of specific enzymes. This complicated system helps produce adenosine triphosphate, the energy currency of all cells, and other molecules critical for colorectal cancer cell growth.
The researchers found that colorectal cells with the PIK3CA mutation broke down significantly more glutamine than cells without the mutation. The researchers identified several enzymes involved in the process that are more active in the mutant cancer cells than in other cell types, explaining the increased need for glutamine. These enzymes become overactive in the mutant cancer cells due to a cascade of signals led by the protein encoded by mutant PIK3CA gene. This finding represents a novel and important link between the common PIK3CA mutation and altered glutamine metabolism in cancer cells.
Zhenghe John Wang, PhD, professor of genetics and genome sciences and co-leader of the Cancer Genetics Program at Case Western Reserve University School of Medicine helped lead the study. “In layman’s terms, we discovered that colon cancers with PIK3CA oncogenic mutations are addicted to glutamine, a particular nutrient for cancer cells. We also demonstrated that these cancers can be starved to death by depriving glutamine with drugs.”
When the researchers lowered the amount of glutamine available to mutant cancer cells growing in laboratory dishes, the cancer cells died. This discovery led the team to investigate the effects of blocking glutamine availability in mice with colorectal cancer tumors containing the common PIK3CA mutation. Wang and colleagues found that exposing these mice to a compound that blocks glutamine metabolism consistently suppressed tumor growth. They did not observe the same effect on tumors without the mutation. Together, these results provide a promising new therapeutic avenue to suppress growth of colorectal tumors with the PIK3CA mutation. The researchers have filed a patent application based on the unique mechanism of tumor suppression they have identified and the work is available for licensing.
“This study provides the basis for a colon cancer treatment clinical trial that will be started in the summer at the University Hospitals Seidman Cancer Center,” according to Neal Meropol, MD, Dr. Lester E. Coleman, Jr. Professor of Cancer Research and Therapeutics, chief of the division of hematology and oncology, and principal investigator for the trial. The phase I/II study will test the effects of a glutamine metabolism inhibitor in patients with advanced colorectal tumors.
The Latest on: Colorectal cancers
via Google News
The Latest on: Colorectal cancers
- Psoriasis Tied to Increased Cancer Riskon October 16, 2019 at 7:00 am
and a 45 percent increased risk for pancreatic cancer. Any degree of psoriasis, severe or not, was significantly associated with colorectal cancer, non-Hodgkin’s lymphoma, and cancers of the kidney ...
- Our View: Awareness, early detection crucial for all types of canceron October 16, 2019 at 3:17 am
... four times as many Americans — approximately 143,000 according to the National Cancer Institute — will die of lung cancer this year than breast cancer. More will also die of colon and rectal ...
- Screen for colorectal cancer at age 45, American Cancer Society recommendson October 16, 2019 at 2:06 am
In the sprig of 2018, the American cancer Society changed its recommendations about colorectal cancer screening in response to more fatal cases in people under 50. They now recommend that average-risk ...
- Never Too Young: A 30-Something Battles Hereditary Colon Canceron October 14, 2019 at 8:29 am
Hensel was stunned and completely unprepared for what it might mean. Five days later, the doctor’s prediction was confirmed. He had Stage 3 colon cancer. The cancer had spread to his lymph nodes.
- Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanismson October 13, 2019 at 3:15 pm
Metastatic colorectal cancer (CRC) with a mismatch repair-deficiency (MMR-D)/microsatellite instability-high (MSI-H) phenotype carries unique characteristics such as increased tumour mutational burden ...
- Promega Hosts Fight Colorectal Cancer (Fight CRC) Research Advocacy Training and Support (RATS) Programon October 11, 2019 at 1:32 pm
Promega Corporation this week is hosting a hands-on research academy for colorectal cancer survivors, caregivers and other members of the Fight Colorectal Cancer (Fight CRC) Research Advocacy Training ...
- Swizz Beatz, Styles P, and Jadakiss take a stand against colon canceron October 10, 2019 at 2:00 pm
African-American men are a population with an extremely high-risk rate for getting and dying from colon cancer. These statistics is not only due to their genetics, but also the stigma around getting ...
- Response gene to complement 32 expression in macrophages augments paracrine stimulation-mediated colon cancer progressionon October 10, 2019 at 10:40 am
However, whether RGC-32 expression in macrophages could play a potential role in tumor progression remain unclear. Here we identified that increasing RGC-32 expression in colon cancer and tumor ...
- New Colorectal Cancer Vaccine May Help Pancreatic Patients Tooon October 8, 2019 at 2:27 pm
Surgery and chemotherapy have long been the primary treatment options for colorectal cancer. Even then, survival rates can be low, if the cancer is not detected early. Now, researchers are fighting ...
- Global Market of Colorectal Cancer Therapeutics Is Expected To Reach in Terms of Revenue USD 9.8 Billion At A CAGR of 1.9% Till 2024on October 7, 2019 at 4:30 am
Oct 07, 2019 (AmericaNewsHour) -- Colorectal Cancer Therapeutics is a medical process which is used to treat cancer of colon and the rectum. This colorectal cancer starts either on colon or rectal and ...
via Bing News